SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-22-009865
Filing Date
2022-01-14
Accepted
2022-01-14 16:10:55
Documents
12
Period of Report
2022-01-13
Items
Item 1.02: Termination of a Material Definitive Agreement

Document Format Files

Seq Description Document Type Size
1 8-K d263241d8k.htm   iXBRL 8-K 23206
  Complete submission text file 0001193125-22-009865.txt   148837

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA xfor-20220113.xsd EX-101.SCH 2892
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE xfor-20220113_lab.xml EX-101.LAB 18888
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE xfor-20220113_pre.xml EX-101.PRE 11860
6 EXTRACTED XBRL INSTANCE DOCUMENT d263241d8k_htm.xml XML 3475
Mailing Address 61 NORTH BEACON STREET 4TH FLOOR BOSTON MA 02134
Business Address 61 NORTH BEACON STREET 4TH FLOOR BOSTON MA 02134 857-529-8300
X4 Pharmaceuticals, Inc (Filer) CIK: 0001501697 (see all company filings)

IRS No.: 273181608 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38295 | Film No.: 22531990
SIC: 2836 Biological Products, (No Diagnostic Substances)
Office of Life Sciences